Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / day one wins fda nod brain cancer therapy ojemda

VIRX - Day One wins FDA nod brain cancer therapy Ojemda

April, 23 2024 01:59 PM Viracta Therapeutics Inc.

2024-04-23 13:59:37 ET

More on Day One Biopharma, Viracta, etc.

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Viracta slides on lower response rate in trial for lymphoma treatment cohort
Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share
Seeking Alpha’s Quant Rating on Day One Biopharmaceuticals
Historical earnings data for Day One Biopharmaceuticals

For further details see:

Day One wins FDA nod brain cancer therapy, Ojemda

Stock Information

Company Name:	Viracta Therapeutics Inc.
Stock Symbol:	VIRX
Market:	NASDAQ

VIRX VIRX Quote VIRX Short VIRX News VIRX Articles VIRX Message Board

Get VIRX Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.